An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM
Launched by QUEEN MARY UNIVERSITY OF LONDON · Aug 8, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to improve health outcomes for young children who are recovering from a serious form of malnutrition called complicated severe acute malnutrition (SAM). SAM is a life-threatening condition that affects millions of children worldwide, especially those who also have illnesses like pneumonia, diarrhea, or malaria. The trial aims to find better ways to support these children after they leave the hospital, where they often face challenges in their home environments, such as poverty and social issues. Researchers will test different support programs to see which ones help reduce hospital readmissions and improve nutrition recovery.
To participate in this trial, children must be between 6 and 59 months old and have been hospitalized for complicated SAM. It’s important that their caregivers are willing and able to bring them to the study clinic for all visits and can provide consent for their participation. Throughout the trial, caregivers and children will receive special support as researchers gather information on how effective these new approaches are in helping the children recover and stay healthy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 6-59 months, of either sex
- • Hospitalised with complicated severe acute malnutrition, as per WHO definition
- • Started transition to RUTF
- • Caregiver willing and able to attend the study clinic for all visits
- • Caregiver able and willing to give informed consent
- Exclusion Criteria:
- • Any acute or chronic condition which mean that receipt of one or more study interventions, or participation in the trial, would not be advisable.
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Harare, , Zimbabwe
Harare, , Zimbabwe
Lusaka, , Zambia
Harare, , Zimbabwe
Lusaka, , Zambia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported